NGVB Logo


Report Summary

Effects of Co-Administration of NY-ESO-1 TCR genetically modified T cells and Hematopoietic Stem Cells (HSCs) in HLAA2.1/Kb mice


Study Summary

Overall Study Design 
 
Propose to co-administer genetically modified T cells and stem cells both expressing an NY-ESO-
1 TCR With this approach the engrafted genetically modified stem cells will generate a source for 
constant renewal of genetically modified T cells that will be able to recognize and kill the tumor 
cells expressing the NY-ESO-1 antigen 
 
The objective of this study is to assess the safety of this approach and to test that the co-
administration of stem cells and T cells genetically modified to express an NY-ESO-1 TCR do not 
negatively impact the engraftment or cell lineage differentiation of the stem cells and the 
persistence of the T cells or the stem cell-derived progeny 
More details on this study are available to registered users. To get access, you need to:
  1. Have an NGVB account: click here to create one
  2. Send an e-mail to the NGVB Manager to request access:

    NGVB Manager
    317-274-4519
    Please enable JavaScript in your browser to see the e-mail address.